Investigators described the development of a CAR against the six-transmembrane epithelial antigen of prostate-1 (STEAP1), which is expressed in ∼90% of prostate cancers, and subgroups of other malignancies.
[Molecular Therapy-Oncolytics]
Home Newsletters Cell Therapy News Development of STEAP1 Targeting Chimeric Antigen Receptor for Adoptive Cell Therapy against...
